NKTR-214 Shows Activity in Phase I RCC Study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Nektar Therapeutics presented positive phase I data for Nektar’s lead immuno-oncology agent, NKTR-214, in patients with renal cell carcinoma.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login